Dr Hendrik-Tobias Arkenau
Hendrik-Tobias Arkenau, M.D., Ph.D.
Executive Medical Director, Drug Development Unit, Sarah Cannon Research Institute UK
Dr. Arkenau has vast experience in early oncology clinical drug development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before joining Sarah Cannon Research UK, he was senior clinical fellow at the Royal Marsden Hospital and team leader for early drug development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.